ReviewFrontiers in digital health2025
The implementation of digital biomarkers in the diagnosis, treatment and monitoring of mood disorders: a narrative review.
Review in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Screening for depression risk via smartphone narratives with fully fine-tuned WavLM.Scientific reports · 2026Article
- Bioinformed idiographic symptom networks to identify neurobiological predictors of affective-state transitions in bipolar disorder.Imaging neuroscience (Cambridge, Mass.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mood Disorders are a group of mental health conditions characterized by a disruption of the emotional state that affects the quality of life of the people living with them. Mental Disorders are difficult to diagnose and treat due to the complex processes involved and limitations of the healthcare system. Digital biomarkers have created accessible, long-term, non-invasive, and user-friendly alternatives for the diagnosis, treatment, and monitoring of these conditions. The use of everyday devices like smartphones and smartwatches and specialized tools like actigraphy, in conjunction with powerful statistical tools, artificial intelligence, and machine learning, represents a promising avenue for the implementation of personalized strategies to monitor and treat Mood Disorders, and potentially higher adherence to treatment. We conducted several studies that implement a variety of methodologies and tools to better understand Mood Disorders, using a patient-focused approach with the ultimate goal of identifying better strategies to improve their quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.